GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Shiller PE Ratio

HLS Therapeutics (HLS Therapeutics) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


HLS Therapeutics Shiller PE Ratio Historical Data

The historical data trend for HLS Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Shiller PE Ratio Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

HLS Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of HLS Therapeutics's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Shiller PE Ratio falls into.



HLS Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

HLS Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, HLS Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.17/125.4675*125.4675
=-0.170

Current CPI (Dec. 2023) = 125.4675.

HLS Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.145 98.604 0.185
201406 0.075 99.473 0.095
201409 0.170 99.394 0.215
201412 0.260 98.367 0.332
201503 -0.063 99.789 -0.079
201506 -0.003 100.500 -0.004
201509 -0.015 100.421 -0.019
201512 -0.019 99.947 -0.024
201603 -0.023 101.054 -0.029
201606 -0.015 102.002 -0.018
201609 -0.008 101.765 -0.010
201612 -1.103 101.449 -1.364
201703 -0.022 102.634 -0.027
201706 -0.015 103.029 -0.018
201709 -0.024 103.345 -0.029
201712 -0.403 103.345 -0.489
201803 -0.190 105.004 -0.227
201806 -0.020 105.557 -0.024
201809 -0.720 105.636 -0.855
201812 0.020 105.399 0.024
201903 -0.140 106.979 -0.164
201906 -0.060 107.690 -0.070
201909 -0.060 107.611 -0.070
201912 -0.420 107.769 -0.489
202003 0.004 107.927 0.005
202006 -0.200 108.401 -0.231
202009 -0.050 108.164 -0.058
202012 -0.230 108.559 -0.266
202103 -0.150 110.298 -0.171
202106 -0.070 111.720 -0.079
202109 -0.060 112.905 -0.067
202112 -0.130 113.774 -0.143
202203 -0.110 117.646 -0.117
202206 -0.280 120.806 -0.291
202209 -0.140 120.648 -0.146
202212 -0.200 120.964 -0.207
202303 -0.180 122.702 -0.184
202306 -0.290 124.203 -0.293
202309 -0.210 125.230 -0.210
202312 -0.170 125.468 -0.170

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


HLS Therapeutics  (OTCPK:HLTRF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


HLS Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (HLS Therapeutics) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA 03-21-2013